In this episode we welcome Rob Roscow, Co-Founder & Chief Scientific Officer at Mydecine Innovations Group.
Mydecine has government, military, and academic research contracts across numerous countries and is heavily invested in development of a novel molecule pipeline that includes treatments intended for smoking cessation and treatment of PTSD.
I had a chance to meet Rob and the Mydecine team in-person at the 2021 Telluride Mushroom Festival, which was sponsored by Mydecine.
This episode dives into the Mydecine drug development pipeline and the entourage effect of mushrooms through a biopharmaceutical lens.
It's an arena of study which I am largely unfamiliar with, but which is becoming increasingly important in lobbying for the mainstream acceptance and regulatory scrutiny of psychedelic medicines as legitimate and effective therapeutic tools.
","author_name":"Dennis Walker"}